# Emergent Product Development Seattle

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/emergent-product-development-seattle

- Industry: Biotechnology
- Headquarters: Seattle, US
- Website: www.trubion.com
- Total disclosed funding: $32M
- Latest round: Series B (Jul 14, 2004)
- Investors on record: 6

## About

Emergent Product Development Seattle, LLC develops innovative biopharmaceutical products specializing in therapeutic antibodies and glycan-based therapeutics for various medical conditions, including cancer and autoimmune diseases.Founded in 1999 in Seattle, US, Emergent Product Development Seattle, LLC focuses on biopharmaceutical innovations. The company was acquired by Emergent BioSolutions Inc. in August 2010. The latest funding round was a PIPE on October 18, 2006, raising USD 10.00 mn, which is the total amount raised to date. The company has facilitated 5 deals in total.Emergent Product Development Seattle, LLC specializes in the development of biopharmaceutical products, particularly therapeutic antibodies and glycan-based therapeutics. Their core offerings include next-generation antibodies (NGAs) designed to improve treatment efficacy for cancer, autoimmune diseases, and infectious diseases. Through advanced antibody engineering techniques, they cater to healthcare providers, research institutions, and pharmaceutical companies in North America, Europe, and Asia.In 2009, Emergent Product Development Seattle, LLC reported revenue of USD 18.00 mn, with an EBITDA of USD -25.53 mn for the same year. Revenue generation stems from strategic partnerships and collaborations, primarily B2B agreements with pharmaceutical firms and research institutions, involving licensing arrangements for their therapeutic innovations.Emergent Product Development Seattle, LLC aims to launch new therapeutic products addressing emerging health challenges. The company plans to expand into additional markets in Europe and Asia by 2025. The funding raised through the PIPE in October 2006 will support these initiatives, enhancing their product development and market entry strategies.

## Funding rounds

- Series B, Jul 14, 2004, $32M — ARCH Venture Partners, Frazier Healthcare Partners, Oxford Bioscience Partners, Prospect Venture Partners, Relay Ventures, Venrock

## Investors

- ARCH Venture Partners (https://capitalatlas.ai/funds/arch-venture-partners) — Series B
- Frazier Healthcare Partners (https://capitalatlas.ai/funds/frazier-healthcare-partners) — Series B
- Oxford Bioscience Partners (https://capitalatlas.ai/funds/oxford-bioscience-partners) — Series B
- Prospect Venture Partners (https://capitalatlas.ai/funds/prospect-venture-partners) — Series B
- Relay Ventures (https://capitalatlas.ai/funds/relay-ventures) — Series B
- Venrock (https://capitalatlas.ai/funds/venrock) — Series B